| $376M | ||
| $350M | ||
| $215M | ||
| $127M | ||
| $107M | ||
| $100M |
Buys | $2,672,211 | 2 | 5 |
Sells | $4,039,267 | 36 | 95 |
| MOTT DAVID M | director | 2 | $2.67M | 0 | $0 | $2.67M |
| Hohenleitner Susan | Chief Financial Officer | 0 | $0 | 2 | $21,005 | $-21,005 |
| Brady James Parker | Chief Human Resources Officer | 0 | $0 | 2 | $26,438 | $-26,438 |
| Bishop John E | See Remarks | 0 | $0 | 2 | $33,039 | $-33,039 |
| Renz Justin A | Chief Financial Officer | 0 | $0 | 1 | $41,741 | $-41,741 |
| GRAMMER ELIZABETH A | See Remarks | 0 | $0 | 2 | $67,841 | $-67,841 |
| Reilly Joseph James | See Remarks | 0 | $0 | 3 | $113,872 | $-113,872 |
| Kelliher Mike | Chief Business Officer | 0 | $0 | 4 | $164,443 | $-164,443 |
| Foster Eric Duane | Chief Commercial Officer | 0 | $0 | 4 | $234,155 | $-234,155 |
| Williams Laura A | Chief Patient Officer | 0 | $0 | 7 | $1.02M | $-1.02M |
| RAAB MICHAEL | President & CEO | 0 | $0 | 9 | $2.31M | $-2.31M |
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is tenapanor. This drug has successfully completed Phase III clinical trials for treating irritable bowel syndrome with constipation (IBS-C) and is also currently in Phase III development to manage hyperphosphatemia (high serum phosphorus) in adult patients with chronic kidney disease (CKD) who are undergoing dialysis. Ardelyx is also advancing other key pipeline assets, including RDX013, a potassium secretagogue designed to combat hyperkalemia (elevated serum potassium), a significant issue for individuals with compromised kidney and/or heart function. Furthermore, the company is in the early stages of developing RDX020, which targets metabolic acidosis, a serious electrolyte disorder frequently seen in CKD patients. To broaden the reach of tenapanor, Ardelyx has established strategic partnerships with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada, granting them rights for the drug's development and commercialization in their respective regions. Originally incorporated in 2007 as Nteryx, Inc., the company adopted its current name, Ardelyx, Inc., in June 2008. Its headquarters are located in Waltham, Massachusetts.
Over the last 12 months, insiders at Ardelyx, Inc. have bought $2.67M and sold $4.04M worth of Ardelyx, Inc. stock.
On average, over the past 5 years, insiders at Ardelyx, Inc. have bought $3.25M and sold $5.61M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MOTT DAVID M (director) — $2.67M.
The last purchase of 333,333 shares for transaction amount of $1.95M was made by MOTT DAVID M (director) on 2026‑02‑20.
| 2026-05-21 | Sale | RAAB MICHAEL | President & CEO | 22,794 0.0091% | $6.27 | $142,861 | -7.06% | |
| 2026-05-21 | Sale | RAAB MICHAEL | President & CEO | 54,748 0.0219% | $6.27 | $343,133 | -7.06% | |
| 2026-05-21 | Sale | Williams Laura A | Chief Patient Officer | 6,989 0.0028% | $6.27 | $43,804 | -7.06% | |
| 2026-05-21 | Sale | Williams Laura A | Chief Patient Officer | 3,329 0.0013% | $6.27 | $20,865 | -7.06% | |
| 2026-05-21 | Sale | Foster Eric Duane | Chief Commercial Officer | 7,998 0.0032% | $6.27 | $50,127 | -7.06% | |
| 2026-05-21 | Sale | Kelliher Mike | Chief Business Officer | 7,248 0.0029% | $6.27 | $45,427 | -7.06% | |
| 2026-05-21 | Sale | Bishop John E | See Remarks | 2,306 0.0009% | $6.27 | $14,453 | -7.06% | |
| 2026-05-21 | Sale | Brady James Parker | Chief Human Resources Officer | 1,846 0.0007% | $6.27 | $11,570 | -7.06% | |
| 2026-05-21 | Sale | Hohenleitner Susan | Chief Financial Officer | 1,455 0.0006% | $6.27 | $9,119 | -7.06% | |
| 2026-05-21 | Sale | Reilly Joseph James | See Remarks | 3,719 0.0015% | $6.27 | $23,309 | -7.06% | |
| 2026-05-15 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.017% | $6.28 | $261,612 | -5.74% | |
| 2026-04-15 | Sale | RAAB MICHAEL | President & CEO | 41,668 0.017% | $6.29 | $261,954 | -1.21% | |
| 2026-03-16 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.017% | $5.84 | $243,329 | +4.45% | |
| 2026-02-24 | Sale | RAAB MICHAEL | President & CEO | 41,666 0.0164% | $6.25 | $260,621 | -6.71% | |
| 2026-02-20 | Sale | RAAB MICHAEL | President & CEO | 45,982 0.0193% | $5.85 | $268,841 | +6.81% | |
| 2026-02-20 | Sale | Williams Laura A | See Remarks | 8,176 0.0034% | $5.85 | $47,803 | +6.81% | |
| 2026-02-20 | Sale | Foster Eric Duane | Chief Commercial Officer | 10,439 0.0044% | $5.85 | $61,034 | +6.81% | |
| 2026-02-20 | Sale | Kelliher Mike | See Remarks | 9,595 0.004% | $5.85 | $56,099 | +6.81% | |
| 2026-02-20 | Sale | Bishop John E | See Remarks | 3,179 0.0013% | $5.85 | $18,586 | +6.81% | |
| 2026-02-20 | Sale | Brady James Parker | Chief Human Resources Officer | 2,543 0.0011% | $5.85 | $14,868 | +6.81% |
| MOTT DAVID M | director | 3302918 1.3371% | $19.12M | 17 | 0 | +18.09% |
| RAAB MICHAEL | President & CEO | 1720033 0.6963% | $9.96M | 1 | 68 | +248.1% |
| Williams Laura A | Chief Patient Officer | 429093 0.1737% | $2.48M | 1 | 23 | +248.1% |
| Foster Eric Duane | Chief Commercial Officer | 417972 0.1692% | $2.42M | 0 | 5 | |
| Renz Justin A | Chief Financial Officer | 409052 0.1656% | $2.37M | 1 | 22 | +248.1% |
| Kelliher Mike | Chief Business Officer | 357418 0.1447% | $2.07M | 0 | 5 | |
| Bishop John E | See Remarks | 336845 0.1364% | $1.95M | 0 | 2 | |
| GRAMMER ELIZABETH A | See Remarks | 299895 0.1214% | $1.74M | 2 | 44 | +117.06% |
| Brady James Parker | Chief Human Resources Officer | 261066 0.1057% | $1.51M | 0 | 2 | |
| Hohenleitner Susan | Chief Financial Officer | 229078 0.0927% | $1.33M | 0 | 2 | |
| Reilly Joseph James | See Remarks | 149107 0.0604% | $863,329.53 | 0 | 3 | |
| BARRIS PETER J | 10 percent owner | 8752543 3.5431% | $50.68M | 3 | 1 | +14.45% |
| BARRETT M JAMES | 10 percent owner | 8752543 3.5431% | $50.68M | 3 | 1 | +14.45% |
| KERINS PATRICK J | 10 percent owner | 8752543 3.5431% | $50.68M | 3 | 0 | +14.45% |
| KOLLURI KRISHNA KITTU | 10 percent owner | 8752543 3.5431% | $50.68M | 3 | 1 | +14.45% |
| New Enterprise Associates 12, Limited Partnership | 10 percent owner | 8752543 3.5431% | $50.68M | 4 | 0 | +10.87% |
| DRANT RYAN D | 10 percent owner | 7488893 3.0316% | $43.36M | 1 | 0 | +13.19% |
| MAKOWER JOSHUA | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| Weller Harry R | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| Viswanathan Ravi | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| Sonsini Peter W. | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| Florence Anthony A. Jr. | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| Sakoda Jon | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| NEA 15 GP, LLC | 10 percent owner | 2665520 1.079% | $15.43M | 2 | 0 | +15.09% |
| SANDELL SCOTT D | 10 percent owner | 2258850 0.9144% | $13.08M | 3 | 8 | +14.45% |
| BASKETT FOREST | 10 percent owner | 2258850 0.9144% | $13.08M | 3 | 8 | +14.45% |
| SCHULTZ PETER G | director | 907429 0.3673% | $5.25M | 1 | 0 | +13.19% |
| Rodriguez Susan | Chief Commercial Officer | 449092 0.1818% | $2.6M | 0 | 16 | |
| Blanks Robert | See Remarks | 314421 0.1273% | $1.82M | 0 | 25 | |
| Rosenbaum David P. | Chief Development Officer | 151373 0.0613% | $876,449.67 | 1 | 55 | +248.1% |
| Seeto Reginald | Chief Operating Officer | 149885 0.0607% | $867,834.15 | 0 | 1 | |
| Kaufmann Mark | Chief Financial Officer | 141418 0.0572% | $818,810.22 | 0 | 8 | |
| Jacobs Jeffrey W | Chief Scientific Officer | 119483 0.0484% | $691,806.57 | 0 | 21 | |
| Felsch Robert Ora | See Remarks | 91560 0.0371% | $530,132.40 | 1 | 8 | +248.1% |
| CMEA Ventures VII LP | 10 percent owner | 80990 0.0328% | $468,932.10 | 1 | 2 | +0.13% |
| Korner Paul | EVP, Chief Medical Officer | 54623 0.0221% | $316,267.17 | 0 | 1 | |
| RINGOLD GORDON | director | 25000 0.0101% | $144,750.00 | 3 | 0 | +13.84% |
| JUE GEORGE | VP, Operations | 24134 0.0098% | $139,735.86 | 0 | 1 | |
| Caldwell Jeremy S | EVP, Chief Scientific Officer | 17985 0.0073% | $104,133.15 | 0 | 3 | |
| Bertrand William C JR | director | 5000 0.002% | $28,950.00 | 1 | 0 | <0.0001% |
$8,217,280 | 112 | 46.33% | $1.48B | |
$607,159,124 | 92 | 3.55% | $1.36B | |
Ardelyx, Inc. (ARDX) | $1,106,309,825 | 63 | 35.64% | $1.43B |
$47,419,530 | 58 | 17.20% | $1.58B | |
$98,235,811 | 43 | 2.44% | $1.44B | |
$50,132,919 | 23 | -23.28% | $1.4B | |
$169,680,836 | 23 | 31.33% | $1.42B | |
$24,007,605 | 16 | -20.65% | $1.4B | |
$73,814,940 | 15 | -4.77% | $1.45B | |
$48,220,484 | 14 | 2.13% | $1.37B | |
$278,247,340 | 12 | 58.08% | $1.44B | |
$5,794,001 | 10 | 23.26% | $1.44B | |
$117,959,652 | 9 | -12.47% | $1.31B | |
$1,580,951 | 9 | -14.18% | $1.44B | |
$93,268,646 | 8 | -37.22% | $1.52B | |
$46,235,722 | 6 | -31.77% | $1.39B | |
$25,999,974 | 4 | 0.00% | $1.41B | |
$103,599,972 | 2 | -36.81% | $1.41B | |
$23,993,224 | 1 | 9.82% | $1.45B |
| Increased Positions | 120 | +47.62% | 31M | +19.19% |
| Decreased Positions | 111 | -44.05% | 25M | -15.71% |
| New Positions | 39 | New | 14M | New |
| Sold Out Positions | 26 | Sold Out | 13M | Sold Out |
| Total Postitions | 261 | +3.57% | 167M | +3.48% |
| Blackrock, Inc. | $128,065.00 | 8.57% | 20.82M | +75,727 | +0.36% | 2025-09-30 |
| Vanguard Group Inc | $112,971.00 | 7.56% | 18.37M | +2M | +14.58% | 2025-09-30 |
| Janus Henderson Group Plc | $85,018.00 | 5.69% | 13.82M | -1M | -8.19% | 2025-09-30 |
| Macquarie Group Ltd | $64,302.00 | 4.3% | 10.46M | -1M | -8.74% | 2025-09-30 |
| State Street Corp | $59,770.00 | 4% | 9.72M | -123,181 | -1.25% | 2025-09-30 |
| Marshall Wace, Llp | $55,000.00 | 3.68% | 8.94M | -2M | -20.51% | 2025-09-30 |
| Millennium Management Llc | $46,998.00 | 3.15% | 7.64M | -4M | -34.48% | 2025-09-30 |
| Geode Capital Management, Llc | $35,404.00 | 2.37% | 5.76M | +90,698 | +1.6% | 2025-09-30 |
| Nuveen, Llc | $31,826.00 | 2.13% | 5.17M | +2M | +48.28% | 2025-09-30 |
| D. E. Shaw & Co., Inc. | $20,375.00 | 1.36% | 3.31M | +854,384 | +34.75% | 2025-09-30 |